Q2 2026 13F · SEC CIK 1536006
Progeny 3, Inc.
Investment managerFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $1.9B
- Reported positions
- 29
- Top holdings a year, 3 yrs
- +11.4%
- Average holding period
- 4.2 yrs
Progeny 3, Inc. is an investment manager that reported 29 positions worth $1.9B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Cameco Corp (CCJ, 12.4%), Interactive Brokers Group in (IBKR, 9.9%), Api Group Corp (APG, 7.7%). A portfolio copying its top holdings returned 11.4% a year over the last 3 years, against 22.3% for the S&P 500.
Progeny 3, Inc. holdings all 29 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Progeny 3, Inc. bought and sold in Q2 2026, against Q1 2026.
New positions
- AROC Archrock Inc2.2% of 13F
- ASND Ascendis Pharma A/s0.1% of 13F
Added to
- POOL Pool Corp+92.9% shares
- CLBT Cellebrite Di Ltd+77.3% shares
- AMZN Amazon Com Inc+8.2% shares
- SSNC Ss&c Tech Hldgs+5.9% shares
Reduced
- NRP Natural Resource Partners LP-26.6% shares
Sold out
- GFL Gfl Environmental Incwas 4.3%
- ABVX Abivax SAwas 0.1%
- PCVX Vaxcyte Incwas 0.1%
- Ascendis Pharma A/swas 0.1%
- CRNX Crinetics Pharmaceuticals inwas 0.0%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -4.6% /yr
- S&P 500 +11.7%
- 3 years
- +11.4% /yr
- S&P 500 +22.3%
- 5 years
- +5.6% /yr
- S&P 500 +10.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $1.9B | 29 |
| Q1 2026 | $1.9B | 32 |
| Q4 2025 | $1.9B | 37 |
| Q3 2025 | $1.9B | 34 |
| Q2 2025 | $1.8B | 30 |
| Q1 2025 | $1.5B | 30 |
| Q4 2024 | $1.3B | 32 |
| Q3 2024 | $1.2B | 34 |
| Q2 2024 | $1.0B | 29 |
| Q1 2024 | $908.8M | 26 |
| Q4 2023 | $806.4M | 23 |
| Q3 2023 | $733.2M | 21 |
Questions about Progeny 3, Inc.'s portfolio
What stocks does Progeny 3, Inc. own?
Progeny 3, Inc.'s latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 29 positions worth $1.9B. The largest are Cameco Corp (CCJ) at 12.4%, Interactive Brokers Group in (IBKR) at 9.9%, Api Group Corp (APG) at 7.7%, Tic Solutions Inc (TIC) at 6.5% and Ishares Tr (IVV) at 5.4%.
What did Progeny 3, Inc. buy last quarter?
In Q2 2026, Progeny 3, Inc. added a new position in Archrock Inc (AROC), a new position in Ascendis Pharma A/s (ASND), Pool Corp (POOL) (+92.9% shares), Cellebrite Di Ltd (CLBT) (+77.3% shares) and Amazon Com Inc (AMZN) (+8.2% shares), compared with its Q1 2026 filing.
What did Progeny 3, Inc. sell last quarter?
In Q2 2026, Progeny 3, Inc. sold all of Gfl Environmental Inc (GFL), sold all of Abivax SA (ABVX), sold all of Vaxcyte Inc (PCVX), sold all of Ascendis Pharma A/s, sold all of Crinetics Pharmaceuticals in (CRNX) and Natural Resource Partners LP (NRP) (-26.6% shares), compared with its Q1 2026 filing.
How has Progeny 3, Inc.'s portfolio performed?
A portfolio copying Progeny 3, Inc.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned +11.4% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: -4.6% against +11.7%. Over 5 years: +5.6% a year against +10.6%.
When is Progeny 3, Inc.'s next 13F filing due?
13F filings are due 45 days after each quarter ends. Progeny 3, Inc.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.